End Stage Renal Disease Market Size, Industry Report, 2027: Grand View Research, Inc.

Posted on
by

End Stage Renal Disease Market Size, Industry Report, 2027: Grand View Research, Inc.

Grand View Research, Inc. – Market Research And Consulting
Increasing number of patients suffering from hypertension and diabetes is another key factor driving the overall market. Approximately, one-third of the population with diabetes develop chronic kidney disease and it is the most common cause of end stage renal disease. Hypertension is mainly caused due to high blood pressure, which significantly increases the risk of end stage renal disease.

End Stage Renal Disease Market Growth & Trends

The global end stage renal disease market size is anticipated to reach USD 172.0 billion by 2027, exhibiting a CAGR of 12.4% over the forecast period, according to a new report by Grand View Research, Inc. Increasing number of patients suffering from kidney failure or end stage renal disease and rising prevalence of hypertension and diabetes are driving the market for end stage renal disease.

Chronic kidney disease (CKD) is one of the major causes of an increase in kidney failure rates among patients. According to the Centers for Disease Control and Prevention (CDC), approximately 37 million people in U.S suffer from CKD, whereas globally more than 500 million people (12-18% of the world population) are affected. Moreover, at present, the highest prevalence rate of CKD is in China, U.S., Taiwan, Japan, Germany, France, Belgium, Africa, and Rest of Asia. It is also estimated that the number of cases of end-stage renal disease or CKD will increase among the elderly population, especially in developing countries, such as China, India, and countries in Africa.

Technological advancements in the treatment of renal failure is another factor expediting the overall market growth. For instance, a wearable artificial kidney (WAK) is a portable dialysis device designed to enable patients to live healthier as it controls blood pressure, improves clearance of wastes from the blood, and allows end-stage renal disease or CKD patient for a less strict diet, resulting in lower fluid weight gain with less stress on the heart. Thus, WAK has the potential to reduce mortality in dialysis patients, thereby improving an end-stage renal disease patient’s quality of life. The WAK prototypes designed and patented by innovative firms have been approved for human clinical trials by the U.S. FDA in 2016 with great success.

Key players in the market for end-stage renal disease include Nipro Corporation; Fresenius Medical Care AG & Co. KGaA; Baxter International, Inc.; Medtronic Plc; B. Braun Melsungen AG; BD; Asahi Kasei Medical Co., Ltd; Cantel Medical; Nikkiso Co., Ltd; and JMS Co. Ltd. For instance, in October 2019, Fresenius Medical Care has received breakthrough device designation by U.S. FDA for its new hemodialysis machine that aims to prevent blood clotting without the use of any medication.

Canada end stage renal disease market size

Request a free sample copy or view report summary:
www.grandviewresearch.com/industry-analysis/end-stage-renal-disease-market/request/rs1

End Stage Renal Disease Market Report Highlights

  • Based on treatment, the dialysis segment dominated the market for end stage renal disease in 2019 owing to its ease of use and emergency convenience

  • Asia Pacific led the market in 2019 owing to the large population of patients with CKD/ESRD and higher incidence of hypertension and diabetes in the region

  • Key players operating in the market include Nipro Corporation; Fresenius Medical Care AG & Co. KGaA; Baxter International, Inc.; Medtronic Plc; B. Braun Melsungen AG; BD; Asahi Kasei Medical Co., Ltd; Cantel Medical; Nikkiso Co., Ltd; and JMS Co. Ltd.

Inquiry Before Buying: www.grandviewresearch.com/inquiry/450244/ibb

End Stage Renal Disease Market Segmentation

Grand View Research has segmented the global end stage renal disease market on the basis of treatment and region:

End Stage Renal Disease Treatment Outlook (Revenue, USD Million, 2016 – 2027)

  • Transplantation

  • Dialysis

    • Peritoneal Dialysis

    • Hemodialysis

    • Wearable Artificial Kidney

End Stage Renal Disease Regional Outlook (Revenue, USD Million, 2016 – 2027)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific (APAC)

    • Japan

    • China

    • India

    • Australia

    • South Korea

  • Latin America (LATAM)

    • Mexico

    • Brazil

    • Argentina

    • Colombia

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

If you need specific information, which is not currently within the article, we will provide it to you as a part of customization

Request a Free Analyst Call:  www.grandviewresearch.com/request-free-consultation/450244/rfac

Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: United States
Website: https://www.grandviewresearch.com/industry-analysis/end-stage-renal-disease-market